To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP), define the grading criteria of adverse events after P-ESWL and ERCP, and analyze the efficacy of P-ESWL and ERCP, which will provide evidence-based medical evidence to guide physicians' clinical practice.

Currently, pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred treatment for pancreatic duct stones. Although some studies had confirmed the safety and efficacy of P-ESWL and ERCP, the sample size were small and the follow-up period were short. Therefore, investigators designed this study with a large sample and a long follow-up period to clarify the efficacy and safety of P-ESWL and ERCP, so as to guide clinical work, standardize the diagnosis and treatment process of adverse events.

Inclusion Criteria:

• Patients hospitalized in Changhai Hospital from 2011.03.01 to 2018.06.30.
• Painful patients with chronic pancreatitis.
• Patients who completed pancreatic extracorporeal shock wave lithotripsy.

Exclusion Criteria:

• Patients who diagnosed pancreatic cancer within 2 years after diagnosing chronic pancreatitis.
• Patients who refused to participate in the study.

Patients hospitalized in Changhai Hospital from 2011.02.01 to 2018.06.30.